-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellectis Exits Lasme-Cel And Eti-Cel Development To Focus On In Vivo Gene Editing Pipeline, Targeting Cash Runway Extension Into H2 2028

Benzinga·09/14/2026 07:59:18
语音播报
  • Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectively
  • Transformation supported by continuing existing cell therapy partnerships while exiting lasme-cel and eti-cel development
  • Realignment of the operating model targeting Cellectis cash runway extension into H2 2028